Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Publication Date: June 20, 2022
Last Updated: June 21, 2022
Summary of Recommendations (all are conditional)
Continue the current dose of methotrexate, leflunomide, hydroxychloroquine, and/or sulfasalazine (nonbiologic DMARDs) for patients undergoing elective THA or TKA. (Level of Evidence: Low - Moderate) ( Conditional , Moderate )
607
Title
Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Authoring Organizations
American Association of Hip and Knee Surgeons
American College of Rheumatology